BioNTech's cancer drug candidate BNT111 showed promising results in a Phase 2 trial for advanced melanoma patients, with a significant improvement in response rates when combined with a checkpoint inhibitor. The company is shifting focus to cancer drug development amid declining COVID-19 vaccine sales.